20 articles
A landmark meta-analysis of 29,625 people finds plasma p-tau217 detects Alzheimer's pathology with ~88% sensitivity and specificity.
Plasma p-tau217 accurately detects preclinical Alzheimer's in cognitively normal adults, potentially enabling earlier intervention.
A fully automated plasma p-tau217 test accurately identifies Alzheimer's pathology across 1,767 patients in primary and secondary care settings.
Plasma eMTBR-tau243 outperforms current tau biomarkers in identifying tau tangle pathology and predicting cognitive decline in Alzheimer's disease.
New biomarker could identify dementia risk decades before symptoms appear, enabling earlier intervention strategies.
New study shows plasma pTau217 test reliably identifies Alzheimer's pathology in the brain, even when other dementia types are present.
Researchers developed plasma p-tau217 clocks that predict when cognitively healthy people will develop Alzheimer's symptoms within 3-4 years.
New p-tau217 blood test forecasts Alzheimer's symptoms within 3-4 years, potentially revolutionizing early intervention strategies.
Brain-derived pTau217 blood test shows superior accuracy for detecting Alzheimer's pathology compared to existing tests.
A Mayo Clinic study reveals the Lumipulse p-tau217/Aฮฒ42 plasma ratio has variable accuracy in detecting Alzheimer's amyloid pathology.
New blood test using 7,000 proteins creates biological aging clock and disease trajectory that better predicts Alzheimer's risk than current methods.
A 7-protein plasma panel predicts Alzheimer's with AUC >0.88, validated across 10,000+ samples from multiple cohorts and platforms.
Comprehensive review reveals TPE could shift from reactive treatment to preventative therapy for cardiovascular, metabolic, and neurological aging.
New evidence-based guideline defines performance thresholds for blood tests that can replace costly PET and CSF testing in specialized AD care.
A licensing deal for 9 specialized Tau antibodies may help distinguish Alzheimer's from other brain diseases years before symptoms appear.
Large study reveals women accumulate toxic tau proteins faster than men, potentially explaining higher Alzheimer's risk.
New research shows tau pathology disrupts neuronal cargo transport before tangles form โ and a kinase inhibitor can reverse it.
French study reveals antibody trajectory patterns that could guide treatment decisions in thrombotic thrombocytopenic purpura.
A 19-year cohort study maps how amyloid and tau shift in CSF across the full Alzheimer spectrum, pinpointing the optimal intervention window.
Scientists discover tau isn't just an Alzheimer's villain โ it's essential for encoding lasting memories in healthy neurons.
